R	EPORT DOC	UMENTATIOI	N PAGE		Form Approved OMB No. 0704-0188		
Public reporting burden for this data needed, and completing a this burden to Department of D	collection of information is estir and reviewing this collection of in defense, Washington Headquart	nated to average 1 hour per resp formation. Send comments rega ers Services, Directorate for Infor	onse, including the time for revieurding this burden estimate or an mation Operations and Reports	y other aspect of this c (0704-0188), 1215 Jeff	ching existing data sources, gathering and maintaining the ollection of information, including suggestions for reducing erson Davis Highway, Suite 1204, Arlington, VA 22202-h a collection of information if it does not display a currently		
valid OMB control number. PL	EASE DO NOT RETURN YOU	R FORM TO THE ABOVE ADDR	RESS.				
1. REPORT DATE (DL 16-11-2012	REPORT DATE (DD-MM-YYYY) -11-2012  2. REPORT TYPE R&D Status Report (Quarte		)uarterly)		<b>DATES COVERED</b> (From - To) 7-08-2012 to 16-11-2012		
4. TITLE AND SUBTIT		-	yuurterry)	5a.	CONTRACT NUMBER R0011-12-C-0063		
		•			GRANT NUMBER		
Of Essential Genes I	Necessary to Impart I	ine		NA NA			
				5c.	PROGRAM ELEMENT NUMBER		
6. AUTHOR(S)					PROJECT NUMBER		
John Glass				N/			
Tony Yee				5e. NA	TASK NUMBER		
Tony Tec					WORK UNIT NUMBER		
			NA				
	SANIZATION NAME(S)	AND ADDRESS(ES)			PERFORMING ORGANIZATION REPORT		
J. Craig Venter Insti 9704 Medical Cente					R0011-12-C-0063.2		
Rockville, MD 2085					10011 12 0 0003.2		
	NITORING AGENCY N	AME(S) AND ADDRESS	S(ES)		SPONSOR/MONITOR'S ACRONYM(S)		
DARPA, MTO	ries ATCC			DA	ARPA		
Prog: Living Founda 675 N Randolph St	les ATGC			11.	SPONSOR/MONITOR'S REPORT		
Arlington, VA 2220	3				NUMBER(S)		
8,				NA			
12. DISTRIBUTION / A	VAILABILITY STATEN	ENT		•			
Approved for public	release; distribution	is unlimited					
13. SUPPLEMENTAR' NA	YNOTES						
have continued to de genome with a reason	elete genes and gene on able doubling time	clusters from the starti	ng genome ( <i>M. myco</i> lso made progress on	ides JCVI-syn1 the design and	essential for life. Toward that end, we .0). To date, the smallest viable synthesis of a minimal genome. and transplantation experiments are in		
15. SUBJECT TERMS NA							
16. SECURITY CLASS	SIFICATION OF:		17. LIMITATION OF ABSTRACT	18. NUMBER OF PAGES	19a. NAME OF RESPONSIBLE PERSON Tony Yee		
a. REPORT	b. ABSTRACT	c. THIS PAGE	UU	5	19b. TELEPHONE NUMBER (include area		
UU	UU	UU			code) 301 795 7133		



Report Title: R&D Status Report (Quarterly)

Report Number: HR0011-12-C-0063.2

Reporting Period: August 17, 2012 to November 16, 2012

Contract No.: HR0011-12-C-0063

Performing Organization: J. Craig Venter Institute

9704 medical Center Drive

Rockville, MD 20850

USA

Author of Report: John Glass, Anthony Yee

Principal Investigators: Hamilton Smith, Clyde Hutchison

### <u>Abstract</u>

We are working towards the goal of creating a bacterium that contains only the set of genes that are essential for life. Toward that end, we have continued to delete genes and gene clusters from the starting genome (*M. mycoides* JCVI-syn1.0). To date, the smallest viable genome with a reasonable doubling time is 778 kb. We have also made progress on the design and synthesis of a minimal genome. Construction of the initial design of minimized 1/8<sup>th</sup> genome molecules is complete, and assembly and transplantation experiments are in progress.

Sponsored by

Defense Advanced Research Projects Agency

Microsystems Technology Office (MTO)

Program: Living Foundries: Advanced Tools and Capabilities for Generalizable Platforms (ATCG)

Issued by DARPA/CMO under Contract No: HR0011-12-C-0063

The views expressed are those of the author and do not reflect the official policy or position of the Department of Defense or the U.S. Government.

Approved for Release; Distribution is Unlimited

(HR0011-12-C-0063)

 Section
 Summary
 2

 Introduction
 2

 Methods, Assumptions and Procedures
 3

 Results and Discussion
 4

 Conclusion
 5

 Planned Activities for the Next Reporting Period
 5

 Program Financial Status
 5

## **Summary**

The goal of the project is to create a cell that contains only the set of genes that are essential for life under ideal laboratory conditions. We are working to minimize *Mycoplasma mycoides* JCVI-syn1.0 (the synthetic version of *Mycoplasma mycoides* subsp *capri*) using two approaches:

- Top Down: remove genes and clusters of genes one (or a few) at a time, proceeding only if the reduced strain is viable, with a reasonable growth rate
  - o The genome has been reduced to 778 kb and found to be viable
  - o Combinatorial assembly of eight 1/8<sup>th</sup> genome molecules has been demonstrated
    - Will allow simultaneous deletions to be made on each 1/8 molecule
- Bottom Up: design our best guess as to the content of a minimal genome and synthesize it from oligonucleotides
  - o Synthesis of the initial design of the minimal 1/8<sup>th</sup> molecules has been completed
  - Assembly and transplantation experiments are underway
  - The first 1/8<sup>th</sup> genome molecule to be synthesized has been assembled into a full genome and transplanted
    - The resultant genome (870 kb) was found to be viable.
    - Strain grows very slowly, forming colonies in approximately 6 days
    - Data from the top-down strategy shows that one or two deleted areas could be causing the slow growth
    - A replacement 1/8<sup>th</sup> molecule with these two suspected deletions added back is being synthesized

### **Introduction**

The primary goal of this research is to make a minimal bacterial cell. J. Craig Venter Institute (JCVI) will construct a new strain of the bacterium *Mycoplasma mycoides*, controlled by a genome that contains only essential genes. The minimal cell will (i) define the minimal set of genetic functions essential for life under ideal laboratory conditions, (ii) discover the set of genes of currently unknown function that are essential and to determine their functions, (iii) serve as a simple system for cell modeling, (iv) allow for modularization of the genes for each process in the cell (translation, replication, energy production, etc.) and to design a cell from those modules, and (v) allow more complex cells to be built by adding new functional modules.

The starting point for minimization is the synthetic genome *M. mycoides* JCVI-syn1.0. There are two approaches for minimization:

1. Top Down: Start with the full size viable *M. mycoides* JCVI-syn1.0 synthetic genome. Simultaneously remove genes and clusters of genes one (or a few) at a time from sections of the genome. Periodically re-test for viability by assembling the reduced genome sections combinatorially, and transplanting the genomes. Only proceed to the next step if the preceding construction is viable and the doubling time is approximately normal.

(HR0011-12-C-0063)


2. Bottom Up: Make our best guess as to the genetic and functional composition of a minimal genome, and then design and synthesize it from oligos. Craig Venter calls this the "Hail Mary" genome (HMG).

# Methods, Assumptions and Procedures

### TOP DOWN APPROACH

The previous approach was to make step-wise deletions of genes and gene segments using the TREC deletion method. This would allow steady progress to be made toward genome minimization. A modified approach has been recently developed and will be used going forward.

A combinatorial assembly method will be followed by the team. In this approach, viable gene cluster deletions will be generated simultaneously using TREC in sections of eight *M. mycoides* genomes. All eight reduced sections would be released by restriction, mixed with full length versions and assembled using homologous recombination in yeast. The resultant genomes will then be transplanted into recipient cells. A schematic representation of the approach is shown below:



### **BOTTOM UP APPROACH**

The design of a minimal genome was previously reported. The design was separated into eight 1/8<sup>th</sup> genome molecules. Each of these 1/8<sup>th</sup> molecules will be assembled into designated areas of 7/8<sup>th</sup> genomes to create complete genomes. The reduced genomes will be transplanted to test for viability.

(HR0011-12-C-0063)

### **Results and Discussion**

TOP DOWN APPROACH

Step-wise Deletion Approach

Targeted, stepwise deletion of genes and gene clusters predicted to be non-essential by transposon mutagenesis was continued, and progress to date is shown below:

	Size	Growth
M. mycoides wild type	1089 kb	++++
M. mycoides JCVI-syn 1.0	1079 kb	++++
M. mycoides JCVI-syn 1.0 – 6RM (17 genes, 17 kb)	1062 kb	++++
M. mycoides JCVI-syn 1.0 – 6RM (17 genes, 17 kb) – 6 IS (14 genes, 13 kb)	1049 kb	++++
M. mycoides JC syn1.0 – 6RM( 12 genes, 17 kb) – 6 IS (12 genes, 9 kb) – ICE (44 genes, 71 kb)	980 kb	++++
M. mycoides JC syn1.0 – 6RM(17 genes, 17 kb) – 6 IS (14 genes, 13 kb) – 18 clusters (148 genes, 235 kb)	814 kb	++

Compared to the starting genome (*M. mycoides JC* syn1.0), the 814 kb genome has 179 genes and 265 kb removed from the genome.

In this reporting period, the team also conducted a large series of experiments aimed at testing deletions of gene clusters for viability:

- Deletion of 122 individual clusters was attempted
- 90 out of 114 genomes (about 79%) have been successfully transplanted; growth rates vary among the deleted strains
- The results from the cluster deletion experiments will be used in the next iterative design of the 1/8 molecules in the Bottom Up Approach

# Combinatorial Approach

The combinatorial assembly approach has been successfully demonstrated. Seven reduced genome sections were mixed with eight parental genome sections and transformed into yeast:

	Section 1	Section 2	Section 3	Section 4	Section 5	Section 6	Section 7	Section 8	Possible Size
Reduced Genome Section	112 kb	67 kb	86 kb	NA	84 kb	93 kb	103 kb	98 kb	764 kb
Parental Genome Section	134 kb	121 kb	133 kb	123 kb	95 kb	119 kb	113 kb	111 kb	946 kb

Complete genomes were assembled via homologous recombination and transplanted into recipient cells. The efficiency of assembling a complete genome was > 80%. The possible 764 kb genome was not located from the combinatorial assembly experiment; however, viable genomes resulted from the combinatorial assembly, which demonstrates that the approach is valid. Colonies were genotyped using a multiplex PCR assay, and size confirmed by gel electrophoresis.

In an alternate experiment, six reduced sections (genome sections 1-3, and 5-8) and one parental section (section 4) were mixed, assembled by homologous recombination and transplanted. In this type of experiment, the resultant genome is will be the smallest possible molecule, but the chance that the transplanted genomes will be slow growing or non-viable is very high. Even though the reduced

(HR0011-12-C-0063)

sections had been previously confirmed as viable, once all of the reduced sections are combined the interaction of the deletions can lead to deleterious effects. Viable mycoplasma colonies with a reduced 778 kb genome were located and genotyped. The expected genome size was 764 kb, but two deletions in section number 8 were not in the transplanted clone. This could be because the yeast clone used to conduct the recombination happened to harbor more than one copy of the mycoplasma genome, and the deleted areas were recombined back into the genome. The colonies formed in approximately 3 days, representing a reasonable growth rate.

### **BOTTOM UP APPROACH**

As previously reported, a minimal genome was designed by the project team. The minimal genome was designed in 1/8<sup>th</sup> genome molecules, so that smaller sections could be tested for viability. Since the last reporting period, all eight of the 1/8<sup>th</sup> genome sections were synthesized and sequence confirmed.

The initial 1/8<sup>th</sup> molecule to be synthesized (HM#2) has been assembled into a full molecule and transplanted. The genome was found to be viable, but displays a slow growth rate (colony formation takes 6 days). Information from deletions made in the Top Down Approach after the minimized genome was designed suggests that there are two viable deletions in HM#2 that cause slow growth. A new HM#2 is being synthesized with these two deletions added back into the sequence, in order to restore the growth rate to previous levels.

Examination of the remaining seven synthetic, minimal 1/8<sup>th</sup> molecules is in progress. They are in various stages of assembly into full genomes and transplantation.

### **Conclusions**

Work has continued on the Top Down Approach to delete genes and gene clusters. Using the combinatorial assembly method will allow parallel work to make deletions around the genome possible. We expect that this will increase the speed and efficiency of this approach.

Testing of the minimal 1/8<sup>th</sup> genome molecules in the Bottom Up Approach is in progress.

### Planned Activities for the Next Reporting Period

We will continue the effort to minimize the genome using targeted deletions and combinatorial assembly methods. We will also continue to test minimized 1/8th genome molecules for functionality. Sections that are found to be non-viable or slow growing will be redesigned and resynthesized.

### **Program Financial Status**

	Planned Expend	Actual Expend (Cumulative to Date)	% Budget Completion	At Completion	Latest Revised Estimate	Remarks
Task 1	\$305,646.19	\$305,646.19	100.0%	\$305,646.19	\$305,646.19	Completed
Task 2	\$869,742.81	\$206,629.34	23.8%	N/A	\$869,742.81	N/A
Cumulative	\$1,175,389.00	\$512,275.54	43.6%	N/A	\$1,175,389.00	N/A

There is no management reserve or unallocated resources.

Based on the currently authorized work:

- Is current funding sufficient for the current fiscal year? Yes
- What is the next fiscal year funding requirement at current anticipated levels? \$1,214,151.00
- Have you included in the report narrative any explanation of the above data and are they cross-referenced? Not applicable; current funding is sufficient for the current fiscal year.